Ap-Pa02
Pseudomonas
Armata Pharmaceuticals, Inc.Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Pseudomonas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aztreonam Liverpool Heart and Chest Hospital NHS Foundation Trust | Phase 4 | BB |
CEFTOLOZANE Joseph L. Kuti, PharmD | Phase 4 | BB |
Tazobactam Joseph L. Kuti, PharmD | Phase 4 | BB |
Amikacin Insmed Incorporated | Phase 3 | BB |
Meropenem Joseph Kuti | Phase 4 | B |
BAY-Q-3939 Bayer | Phase 1 | CC |
Ciprofloxacin Bayer | Phase 1 | CC |
Same molecule, other indications
Ap-Pa02 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →